Latest Articles

Publication Date
Synergistic effects of melatonin and dienogest on pain relief in endometriosis: a randomized controlled trial.

Endometriosis affects 5-10% of reproductive-aged women and is characterized by chronic pelvic pain, dysmenorrhea, dyspareunia, and infertility. Standard hormonal therapies, such as dienogest, effectively manage symptoms, but are often associated …

Published: March 31, 2026, midnight
Hope Medicine Doses First Patient in Phase III Trial of Non-Hormonal Endometriosis Treatment - Femtech Insider

Hope Medicine Doses First Patient in Phase III Trial of Non-Hormonal Endometriosis Treatment Femtech Insider

Published: March 30, 2026, 1:56 p.m.
Endometriosis Hormonal Treatments Compromise Bone Health - Medscape

Endometriosis Hormonal Treatments Compromise Bone Health Medscape

Published: March 30, 2026, 10:41 a.m.
Shared Pathophysiology and Early Detection Biomarkers in Endometriosis and Polycystic Ovary Syndrome (PCOS): Opportunities for AI-Enabled Screening.

Endometriosis and polycystic ovary syndrome (PCOS) are common, multifactorial gynecological disorders shaped by endocrine imbalance, immune dysfunction, metabolic disruption, genetic susceptibility, and environmental exposures. Despite their major contribution to infertility …

Published: March 28, 2026, midnight
Contraceptive-Induced Weight Gain-Myth and Reality Review.

The perception that hormonal contraception causes weight gain is a general belief that frequently hinders the initiation and continuation of effective family planning. This narrative review analyses data from Cochrane …

Published: March 27, 2026, midnight
YWHAZ Loss Is Associated With Endometrial Dysfunction in Proliferative Phase Endometriosis.

Endometriosis is an estrogen-dependent inflammatory disorder frequently associated with infertility and characterized by progesterone resistance and impaired endometrial receptivity. While ectopic lesions define the disease, accumulating evidence indicates that molecular …

Published: March 26, 2026, midnight
EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis - BioSpace

EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis BioSpace

Published: March 23, 2026, 12:47 p.m.
EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis - PR Newswire

EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis PR Newswire

Published: March 23, 2026, 11:30 a.m.
Using artificial intelligence to predict sexual health outcomes in endometriosis: a decision tree model algorithm.

Endometriosis profoundly impairs sexual function through complex interactions between pain, hormonal disturbances, psychological distress, and sociodemographic factors.

Published: March 23, 2026, midnight
Medical Treatment for Endometriosis: One Size Does Not Fit All.

Endometriosis is associated with nociceptive pain, as well as peripheral and central sensitization. Evidence-based treatment suggestions for controlling endometriosis should be based on the convergence of the best scientific evidence, …

Published: March 21, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!